---
authors:
- Barry, Henry C
category: Clinical Review
clinical_significance: High
external_resources:
- title: PubMed Entry
  type: reference
  url: https://pubmed.ncbi.nlm.nih.gov/36791433/
file_path: 2023/02/ketorolac-plus-dexamethasone-is-more-effective-for-pain-reli.md
issue: '2'
keywords:
- Humans
- Ketorolac
- Adult
- Double-Blind Method
- Renal Colic
- Anti-Inflammatory Agents, Non-Steroidal
- Dexamethasone
- Colic
- Pain Management
last_updated: '2025-07-30'
mesh_terms:
- Adult
- Humans
- Ketorolac
- Renal Colic
- Anti-Inflammatory Agents, Non-Steroidal
- Pain Management
- Dexamethasone
- Double-Blind Method
- Colic
original_format: PubMed
pages: '200'
patient_population: Adults
peer_reviewed: true
pmid: '36791433'
processed_date: '2025-07-30'
publication_date: '2023-02-01'
pubmed_enriched: true
pubmed_enriched_date: '2025-07-30'
reading_time_minutes: 5
source: American family physician
specialty:
- Family Medicine
status: processed
tags:
- clinical-review
- family-practice
- clinical-medicine
- pubmed-enhanced
title: Ketorolac Plus Dexamethasone Is More Effective for Pain Relief Than Ketorolac Alone in Adults With Renal Colic.
topics:
- Family Medicine
volume: '107'
---

# Ketorolac Plus Dexamethasone Is More Effective for Pain Relief Than Ketorolac Alone in Adults With Renal Colic.

**Authors:** Barry, Henry C

**Published in:** American family physician | Vol. 107, No. 2 | 2023-02-01

**Links:** [PubMed](https://pubmed.ncbi.nlm.nih.gov/36791433/)

## Clinical Information

**Population:** Adults | **Clinical Significance:** High

## Topics & Specialties

**Specialties:** Family Medicine

**Topics:** Family Medicine

## MeSH Terms

Adult, Humans, Ketorolac, Renal Colic, Anti-Inflammatory Agents, Non-Steroidal, Pain Management, Dexamethasone, Double-Blind Method, Colic

## Article Content

*Full article content to be extracted and formatted from source material.*

## Additional Resources

- [PubMed Entry](https://pubmed.ncbi.nlm.nih.gov/36791433/) (reference)

---

*Processed: 2025-07-30* | *PubMed Enhanced: 2025-07-30*
